The study not only identifies RUNX1 as a novel prospective therapeutic target and a biomarker in NASH but also opens opportunities for exploration of the mechanisms of angiogenesis and inflammation in NASH. This evidence concerns the gene RUNX1 and metabolic dysfunction-associated steatohepatitis.